Biometrics Built Better

B Corp Impact Report 2024

Explore the achievements, sustainability initiatives, and social impact commitments that shaped our business in 2024 and learn how Veramed is helping drive positive change through responsible and sustainable business practices.

Share this article

As a Certified B Corporation, we believe business should be a force for good. Our Impact Report is an opportunity to transparently share the progress we’ve made and the steps we’re taking to create positive outcomes for our people, communities, customers, and the environment.  

In our 2024 Impact Report, you’ll discover how Veramed: 

  • Strengthened corporate governance 
  • Invested in employee well-being and workplace culture 
  • Expanded community engagement and volunteer initiatives 
  • Advanced sustainability programs 
  • Enhanced our environmental performance 

The report also shares updates on our B Corp recertification journey and our commitment to responsible business growth and continuous improvement. 

Download the Report 

Explore the achievements, sustainability initiatives, and social impact commitments that shaped our business in 2024 and learn how Veramed is helping drive positive change through responsible and sustainable business practices.

Veramed B Corp Impact Report 2024

Commitment to Responsible Biometrics. Leading the Way for People, Planet, and Purpose. Learn more about our B Corp journey here.

contact us

Share this article

Stay Connected

Sign up to receive the latest insights, case studies, and Veramed news—straight to your inbox.

Join our mailing list today

Related Posts

View all resources
  • Case study

Trust, retention and continuous improvement: Building an FSP partnership for longevity

Veramed’s long-term FSP partnership with a leading biopharmaceutical company delivers scalable biometrics and data management expertise, helping improve
  • Blog

Flexible teams, consistent thinking: The statistical solution biotechs need

Learn how embedded statistical support helps emerging biotechs bridge the gap between strategy and execution, providing continuous oversight,
  • Blog

Do you really need a DMC? Independent oversight: choose the right approach for your study

Director, Statistics, Zainab Walsh, answers some of the most common questions sponsors ask about DMCs, including when they
  • Case study

Maintaining study integrity in complex data-sharing environments

A large pharmaceutical sponsor needed to manage complex unblinded data access during a highly complex Phase IIb study
  • Publications

Re-Randomization Tests in Clinical Trials: A Simulation Case Study & Practical Guidance

Learn how re-randomization tests can strengthen clinical trial analysis with a simulation case study and practical statistical guidance.
  • Case study

High pressure DMC delivery: Proactive planning to mitigate risk and ensure on-time outputs

Veramed provided independent unblinded statistical support for multiple DMC deliveries for a large pharma client’s Phase 2b double-blind,